8/28/2009

Silence Therapeutics agreed to demonstrate its small interfering RNA delivery technology to Dainippon Sumitomo Pharma for an undisclosed amount. The collaboration could lead to a drug-development deal in 2010, said Iain Ross, Silence Therapeutics' chairman and CEO.

Related Summaries